SAN FRANCISCO (Reuters Health) - A community hepatitis
B screening program targeting mainly underserved foreign-born Asian
residents of New York City found a higher prevalence of infection than
previously reported among Asian populations in the United States.

The physicians reported an overall prevalence of 23.8% among the
1,836 people screened as of June 30. Previous hepatitis screening
programs in the United States have reported prevalence rates of 10% to
15%.

The results represent 1 year of screening, which attracted mostly
China and Korea-born immigrants, said Dr. Alex Sherman, clinical
associate professor of medicine at New York University School of
Medicine. He will present the results of the screening program this
week here at the annual meeting of the American Association for the
Study of Liver Diseases.

In an interview with Reuters Health, Dr. Sherman said many of the
participants haven't had ready access to medical care either because of
language, economics or other reasons. And some of the participants may
not have been aware of their risk of hepatitis B infection or the
medical implications of an untreated infection or that effective
well-tolerated, oral treatments have become available in the last 2 or
3 years that can reduce the risk of cirrhosis and liver cancer.

He speculated that the higher prevalence found in this screening
program might reflect the success of the community outreach effort to
find underserved, foreign-born Asian immigrants. He noted that this was
not a randomized study. People participated in response to the media
campaign and outreach efforts, particularly in the areas of Chinatown
in Manhattan for Chinese immigrants, and Flushing in Queens for Korean
immigrants.

In the program, 99% of the participants were foreign born, 60% from China, about 30% were from Korea, and 7% were from Malaysia.

Of those born in China, 32.9% were infected. Of those born in Korea or other Asian countries, 11.3% were infected.

"Being born in China was one of the risk factors," Dr. Sherman said.

A positive family history was the strongest risk factor. A "yes"
answer to that question was associated with a 42.5% prevalence,
compared with 18.1% among those who said no one else in their family
was infected.

Also, male participants had a higher prevalence than females - at
30.9% and 15.4%, respectively, and those between 19 and 40 years old,
who had a 33.8% prevalence compared with 17.2% for older or younger
participants.

If the participants said they had been previously screened, then
they also had an increased risk of being infected. Many of those people
may have been aware that they were infected and were coming to receive
further medical evaluation and treatment.

Overall, 23.8 % were HBsAg+, and were referred for further
evaluation and treatment; 27.6% carried no immunity and were referred
for vaccination, and 48.6% appeared to have been previously vaccinated.

"We figure that half of the population we screened were eligible for intervention," Dr. Sherman said.

The study was sponsored by a New York City Council grant to the
Asian American Hepatitis B Program (AAHBP), a non-profit,
public/private coalition working with the New York University Center
for the Study of Asian American Health. The AAHBP aims to screen 5000
Asian Americans to determine the prevalence of chronic hepatitis B and
organize a treatment model.